Drug Profile
Research programme: fibroblast growth factor receptor antagonists - sanofi-aventis
Alternative Names: SSR 128129Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator sanofi-aventis
- Class
- Mechanism of Action Fibroblast growth factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in France
- 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
- 04 Sep 2003 Preclinical trials in Cancer in France (unspecified route)